U.S. Communications Stock News

Rithm Property Trust (RPT) opened Q1 2026 with total revenue of US$2.9 million and basic EPS of US$0.43 loss per share, giving investors a fresh look at how the business is tracking after a volatile 2025. Over the past year, revenue has moved from US$18.3 million on a trailing basis in Q4 2025 to US$22.0 million by Q1 2026, while trailing twelve month EPS has shifted from a US$0.36 loss to a US$0.30 loss. With the share price around US$14.43, the latest release puts the spotlight squarely on...

If you are wondering whether Gentex is reasonably priced or offering value at its current share price, the key numbers can give some useful clues before you make any decisions. The stock last closed at US$23.88, with returns of 5.5% over the past week, 9.9% over the past month, 0.8% year to date, 14.1% over the past year, and multi-year returns of an 8.7% decline over three years and a 26.0% decline over five years. Recent share price moves often sit against a backdrop of ongoing product...

DaVita (NYSE:DVA) reports that its integrated kidney care platform has reached profitability earlier than planned. The platform is delivering improved patient outcomes, supporting the company’s focus on value based care. This marks a material shift in DaVita’s business mix, with potential implications for how investors view its role in healthcare services. DaVita is best known for its dialysis clinics, but the integrated kidney care platform points to a broader role in managing chronic...

Investors may be wondering whether Monolithic Power Systems at around US$1,632 per share is still offering value, or if expectations are already fully priced in. The stock has posted returns of 11.1% over the last 7 days, 54.2% over the last 30 days, 74.3% year to date and 181.7% over the past year, with longer term returns of 261.4% over 3 years and 368.4% over 5 years. These strong price moves have kept Monolithic Power Systems firmly on investors' watchlists, as the market reacts to...

Wealthfront (WLTH) closed FY 2026 with Q4 revenue of US$96.1 million and a basic EPS loss of US$1.30, alongside trailing 12 month revenue of US$365.0 million and a trailing basic EPS loss of US$0.74. Over the past six quarters, the company has seen quarterly revenue move from US$80.3 million in Q3 2025 to US$96.1 million in Q4 2026. Basic EPS has shifted from US$0.77 in Q3 2025 to US$0.72, US$0.86 and US$0.75 in the first three quarters of 2026 before turning to a loss of US$1.30 in Q4 2026...

Wondering if JFrog at around US$45.25 is priced for its future potential or already reflects high expectations? This article walks through the numbers so you can judge the valuation for yourself. JFrog’s share price recently closed at US$45.25, with returns of 2.6% over 7 days, 4.4% over 30 days, a negative 24.0% year to date, 33.3% over 1 year, 143.7% over 3 years and a negative 7.7% over 5 years, giving a mixed picture for anyone looking at entry or exit points. Recent news coverage has...

If you are wondering whether SLB at around US$56.15 still offers value or is starting to look stretched, the key is to look past the headline share price and focus on what different valuation methods are saying. Over the short term, the stock has returned 6.6% over 7 days and 8.2% over 30 days, while the year to date return stands at 39.7% and the 1 year return at 67.6%. This may have shifted how investors view both its potential and its risks. Recent coverage has focused on how SLB fits...

Wondering if Opera's recent share price puts it in the bargain bin or the overhyped aisle? This article breaks down what the numbers say about value. At a last close of US$17.23, Opera's share price comes with recent returns of 0.6% over 7 days, 25.6% over 30 days, 21.1% year to date, 16.3% over 1 year, 67.0% over 3 years, and 105.9% over 5 years. These moves sit against a backdrop of ongoing interest in Opera as a software name, with headlines frequently focusing on its role as a browser...

Wondering if Amkor Technology at US$78.10 is priced for perfection or still offers value? This article walks you through what the current market price may be telling you. The stock has recently posted returns of 15.9% over 7 days, 73.0% over 30 days, 82.0% year to date, and 350.3% over 1 year, which can change how investors think about both upside potential and risk. These moves sit against the backdrop of ongoing attention on semiconductor supply chains and packaging capacity, as investors...

Wondering whether Palvella Therapeutics at around US$123.59 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price could mean for you. The stock has seen a 23.2% return year to date and a 386.8% return over the last year, alongside shorter term moves of a 2.7% return over 30 days and a 4.9% decline over the past week. Recent attention on Palvella Therapeutics has centered on how the market is reassessing smaller biotech names...

In April 2026, ZenaTech expanded its global drone and SaaS footprint by registering Phoenix Aero in Lviv, Ukraine, and opening new offices in Seoul and London to support manufacturing, counter-UAS testing, and regional commercial, government, and defense operations. This rapid build-out of on-the-ground teams across EMEA and APAC highlights ZenaTech’s intent to become a key provider of AI-driven autonomous drone solutions and recurring software services in multiple high-demand markets. We’ll...

If you are wondering whether Ciena's current share price reflects its true worth, the recent trading history gives you plenty to think about. The stock last closed at US$520.80, with returns of 2.6% over 7 days, 19.0% over 30 days and 111.7% year to date, plus very large returns over 1 year and the past 3 and 5 years. Recent coverage has focused on Ciena as a key player in communications technology, with attention on how its products fit into growing data and network demand. This context has...

Varonis Systems launched Atlas, an all in one AI security solution integrated with its Data Security Platform. Atlas is designed to help enterprises with AI inventory discovery, security testing, data leak prevention, and compliance. The launch adds a new AI focused layer to Varonis Systems' existing data security offering. For investors watching NasdaqGS:VRNS, Atlas lands at a time when AI security is a central concern for many enterprise IT teams. The company’s shares most recently closed...

If you are wondering whether Wintrust Financial at US$147.91 still offers value or is starting to look stretched, the recent share price and fundamentals give you some clear clues to work with. The stock has held up over the last week with a 0.2% decline. The 30 day return sits at 8.0% and the 1 year return at 35.6%, with longer term returns of 128.2% over 3 years and 108.7% over 5 years. Recent coverage has focused on Wintrust Financial as part of broader discussions around US regional...

Why Getty Realty Stock Is Drawing Attention Now Getty Realty (GTY) has been on some investors’ radar after a stretch of positive total returns over the past year, prompting closer scrutiny of its income profile and recent share performance. See our latest analysis for Getty Realty. Getty Realty’s share price has eased slightly in the very short term, with a 1 day share price return of 0.92% decline and a 7 day share price return of 3.35% decline. However, the 90 day share price return of...

FDA extends Priority Review for Savara’s molgramostim BLA in autoimmune PAP by three months following a major amendment. Regulator cites no new safety, efficacy, or manufacturing concerns in connection with the extension. Extension reflects ongoing review activity for Savara’s lead product candidate, ticker NasdaqGS:SVRA. Savara, listed on NasdaqGS:SVRA, focuses on therapies for rare respiratory diseases, with molgramostim as its most advanced program targeting autoimmune pulmonary alveolar...

If you are wondering whether CNO Financial Group's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock most recently closed at US$43.71, with returns of 0.2% over 7 days, 7.6% over 30 days, 3.6% year to date, 12.3% over 1 year, 106.9% over 3 years and 90.8% over 5 years. This provides plenty of history to measure current pricing against. Recent coverage around CNO Financial Group has centered on its role...

Vail Resorts (NYSE:MTN) reports that an unusually warm winter and record low snowfall have sharply reduced skier visits across its resorts. The company now expects full year results to come in near the lower end of its previously issued guidance. Weather driven disruption to skier visitation is creating a material headwind for resort revenue and in resort spending. For investors watching Vail Resorts, the operational setback comes on top of a weak share price backdrop. NYSE:MTN closed at...

If you are wondering whether ANI Pharmaceuticals at around US$78.64 is priced attractively or already reflects a lot of optimism, the starting point is to understand what the current share price implies about future expectations. The stock shows mixed recent returns, with a 2.8% decline over 7 days, a 6.2% gain over 30 days, a 0.3% return year to date, 12.6% over 1 year, 108.5% over 3 years and 136.3% over 5 years. Recent coverage around ANI Pharmaceuticals has focused on its position within...

If you are wondering whether TransMedics Group at around US$110.93 is still priced attractively or already baking in a lot of optimism, this article walks through the key valuation clues. The stock has had a mixed recent run, with a 4.3% pullback over the last 7 days, an 8.5% gain over 30 days, a 9.6% decline year to date, an 18.6% return over the past year, and a very large 3 year gain of around 40.2%. Recent headlines around TransMedics Group have continued to focus on its position in the...

Innovative Aerosystems has acquired an exclusive perpetual license from Honeywell International (NasdaqGS:HON) for aircraft power generating systems. The transaction covers customer contracts, intellectual property rights, and both OEM and aftermarket assets tied to these systems. This move reshapes how Honeywell participates in aircraft power technologies across commercial and defense programs. For you as an investor, this is a focused portfolio move within Honeywell's aerospace business...

Philip Morris International Inc. reported past first-quarter 2026 results with revenue rising to US$10.15 billion from US$9.30 billion, while net income and diluted EPS from continuing operations eased to US$2.44 billion and US$1.56 respectively, and it updated full-year 2026 EPS guidance to US$7.56–US$7.71. Beyond the headline numbers, the quarter underscored how growth in smoke-free products like IQOS and VEEV, supported by pricing power, is reshaping Philip Morris International’s earnings...

Wondering if Axsome Therapeutics at around US$185.96 is offering fair value or stretching expectations? This breakdown will help you frame what the current price might be implying. The stock has seen a 14.9% return over the last 30 days and a 75.0% return over the last year. The year to date return sits at 4.1%, while the 7 day return is a 1.6% decline. Recent headlines around Axsome have focused on the company as a higher profile name within pharmaceuticals and biotech. This helps explain...

Dave has rolled out new AI products, CashAI and DaveGPT, as part of its core digital banking and lending offering. The company is pairing this AI launch with a focus on triple digit earnings growth, which is drawing increased investor attention. These developments come as Dave's share price sits at $274.56 under the ticker NasdaqGM:DAVE. For investors tracking NasdaqGM:DAVE, the AI rollout is arriving after a sharp share price move that has already put the company on many watchlists. The...